ArticleBlood advances2026
A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe management of essential thrombocythemia (ET) relies on risk stratification; therefore, easily applicable risk scores with improved prognostic value are in demand. The Triple A risk score is a novel model incorporating age, absolute neutrophil, and absolute lymphocyte counts (AAA model). In this study, we aimed to evaluate the predictive performance of Triple A score in ET for survival and its complications in an independent cohort, in addition to refining the model by incorporating absolute monocyte count and neutrophil-to-lymphocyte ratio (NLR). Demographic, clinical, and laboratory data of 565 patients with ET were retrospectively collected. Based on Triple A score, 250 patients were classified as low risk, 228 as intermediate-1 risk, 37 as intermediate-2 risk, and 50 as high risk. Over a median follow-up of 6 years, 10.3% patients developed thrombosis, 4.4% experienced bleeding, 5.1% had post-ET myelofibrosis, and 10.9% died. There were significant differences in overall survival and thrombosis-free survival across risk groups. Monocytosis (>0.8 × 109/L) was associated with increased mortality and its prevalence increased progressively with higher Triple A scores. Elevated NLR was also linked to a higher risk of mortality, and moreover, NLR-monocyte-age-based risk score demonstrated significant differences in survival risk. Consequently, Triple A score is an easy-to-use and reliable tool for predicting survival and thrombosis in ET. Incorporating monocytosis into Triple A (AAA+A model) may further enhance its prognostic accuracy. NLR also demonstrated prognostic value both independently and as component of NLR-monocyte-age-based model, highlighting its potential as a robust tool for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.